Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Biobased Chemicals
Biobased chemical maker Amyris seeks to right financial ship
by Michael McCoy
June 9, 2023
| A version of this story appeared in
Volume 101, Issue 19
The biobased chemical maker Amyris says it is embarking on a restructuring, advised by the consulting firm PwC, that is intended to cut costs by $250 million. Amyris uses fermentation to produce consumer product ingredients such as patchouli and cannabigerol. The firm recently sold its business in squalane and other cosmetic ingredients to Givaudan for up to $350 million, but it continues to lose money. Two lenders to Amyris, Foris Ventures and the chemical maker DSM, have waived defaults on their loans.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter